Glenn D. Braunstein

Dr. Glenn D. Braunstein

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2005 in Archives of internal medicine (1960)
Verified
Journal Article
Open access
PDF file
GBGlenn D. Braunstein
Glenn D. Braunstein
DSDale A. Sundwall
Dale A. Sundwall
MKMolly Katz
Molly Katz
JSJan L. Shifren
Jan L. Shifren
JBJohn E. Buster
John E. Buster
NWNelson B. Watts
Nelson B. Watts
Hypoactive sexual desire disorder, 1 of the 4 common forms of female sexual dysfunction, is characterized by chronic or recurrent deficit in or absence of desire for sexual activity, resulting in personal distress.1

6 January 2021 in Journal of Occupational and Environmental Medicine
Verified
Journal Article
Closed access
GBGlenn D. Braunstein
Glenn D. Braunstein
LSLori Md Schwartz
Lori Md Schwartz
PHPamela Md Hymel
Pamela Md Hymel
JFJonathan Md Fielding
Jonathan Md Fielding
An abstract is unavailable. This article is available as a PDF only.

1 January 2014 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
YZYan Zhou
Yan Zhou
CZConghui Zhao
Conghui Zhao
SGSigal Gery
Sigal Gery
GBGlenn D. Braunstein
Glenn D. Braunstein
RORyoko Okamoto
Ryoko Okamoto
HKH. Phillip Koeffler
H. Phillip Koeffler
Aberrantly activated c-MET signaling occurs in several cancers, promoting the development of c-MET inhibitors. In this study, we found that eight of eight thyroid cancer cell lines (including six anaplastic thyroid cell lines) have prominent expression of c-MET protein. Fifty percent of the thyroid cancer cell lines (four of eight) were growth inhibited by two small molecule c-MET inhibitors (tivantinib and crizotinib) associated with apoptosis and G2–M cell-cycle arrest. However, crizotinib did not inhibit 50% proliferation of thyroid cancer cells (SW1736 and TL3) at a concentration at which the drug completely inhibited ligand-stimulated c-MET phosphorylation. However, tivantinib was less potent than crizotinib at inhibiting c-MET phosphorylation, but was more potent than crizotinib at decreasing cell growth. Suppressing c-MET protein expression and phosphorylation using siRNA targeting c-MET did not induce cell-cycle arrest and apoptosis. Taken together, tivantinib and crizotinib have off-target(s) activity, contributing to their antitumor activity. In vivo study showed that crizotinib markedly inhibited the growth of thyroid cancer cells (SW1736) in immunodeficient mice. In summary, c-MET inhibitors (tivantinib and crizotinib) suppress the growth of aggressive thyroid cancer cells, and this potential therapeutic benefit results from their non–MET-targeting effects. Mol Cancer Ther; 13(1); 134–43. ©2013 AACR.

8 July 2013 in BMC Geriatrics
Verified
Journal Article
Open access
PDF file
JBJeff Borenstein
Jeff Borenstein
HAHarriet Udin Aronow
Harriet Udin Aronow
LBLinda Burnes Bolton
Linda Burnes Bolton
JCJua Choi
Jua Choi
CBCatherine Bresee
Catherine Bresee
GBGlenn D. Braunstein
Glenn D. Braunstein
There is a persistently high incidence of adverse events during hospitalization among Medicare beneficiaries. Attributes of vulnerability are prevalent, readily apparent, and therefore potentially useful for recognizing those at greatest risk for hospital adverse events who may benefit most from preventive measures. We sought to identify patient characteristics associated with adverse events that are present early in a hospital stay. An interprofessional panel selected characteristics thought to confer risk of hospital adverse events and measurable within the setting of acute illness. A convenience sample of 214 Medicare beneficiaries admitted to a large, academic medical center were included in a quality improvement project to develop risk assessment protocols. The data were subsequently analyzed as a prospective cohort study to test the association of risk factors, assessed within 24 hours of hospital admission, with falls, hospital-acquired pressure ulcers (HAPU) and infections (HAI), adverse drug reactions (ADE) and 30-day readmissions. Mean age = 75(±13.4) years. Risk factors with highest prevalence included >4 active comorbidities (73.8%), polypharmacy (51.7%), and anemia (48.1%). One or more adverse hospital outcomes occurred in 46 patients (21.5%); 56 patients (26.2%) were readmitted within 30 days. Cluster analysis described three adverse outcomes: 30-day readmission, and two groups of in-hospital outcomes. Distinct regression models were identified: Weight loss (OR = 3.83; 95% CI = 1.46, 10.08) and potentially inappropriate medications (OR = 3.05; 95% CI = 1.19, 7.83) were associated with falls, HAPU, procedural complications, or transfer to intensive care; cognitive impairment (OR = 2.32; 95% CI = 1.24, 4.37), anemia (OR = 1.87; 95% CI = 1.00, 3.51) and weight loss (OR = 2.89; 95% CI = 1.38, 6.07) were associated with HAI, ADE, or length of stay >7 days; hyponatremia (OR = 3.49; 95% CI = 1.30, 9.35), prior hospitalization within 30 days (OR = 2.66; 95% CI = 1.31, 5.43) and functional impairment (OR = 2.05; 95% CI = 1.02, 4.13) were associated with 30-day readmission. Patient characteristics recognizable within 24 hours of admission can be used to identify increased risk for adverse events and 30-day readmission.

1 May 2018 in Endocrine Practice
Verified
Journal Article
Closed access
MLMark Lupo
Mark Lupo
RGRichard Guttler
Richard Guttler
ZGZsofia Geck
Zsofia Geck
TTTheresa R. Tonozzi
Theresa R. Tonozzi
AKAnja Kammesheidt
Anja Kammesheidt
GBGlenn D. Braunstein
Glenn D. Braunstein

10 November 2017 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
PFPhillip Fleshner
Phillip Fleshner
GBGlenn D. Braunstein
Glenn D. Braunstein
GOGayane Ovsepyan
Gayane Ovsepyan
TTTheresa R. Tonozzi
Theresa R. Tonozzi
AKAnja Kammesheidt
Anja Kammesheidt
The majority of colorectal cancers (CRC) harbor somatic mutations and epigenetic modifications in the tumor tissue, and some of these mutations can be detected in plasma as circulating tumor DNA (ctDNA). Precancerous colorectal lesions also contain many of these same mutations. This study examined plasma for ctDNA from patients undergoing a screening or diagnostic colonoscopy to determine the sensitivity and specificity of the ctDNA panel for detecting CRC and precancerous lesions. Two hundred patients without a history of nonskin cancer had blood drawn before a colonoscopy. Plasma ctDNA was measured with a 96 mutation panel for nine cancer driver genes. The ctDNA results were correlated with the findings at colonoscopy. Of the 200 patients, 176 (88%) had wild‐type DNA, 12 (6%) had mutations detected, and 12 (6%) had indeterminate results. Colonoscopy was normal in 80% of the patients and 20% were found to have polyps. No CRC was found in this study, precluding a determination of true‐positive rate for CRC detection. Our ctDNA panel was positive in 13.2% of patients with colonic polyps found at colonoscopy, while 4.7% of patients with normal colonoscopy also had ctDNA detected, which may represent ctDNA released from a benign process, an occult tumor, or an acquired somatic mutation from clonal hematopoiesis.